Prosecution Insights
Last updated: November 20, 2026
Application No. 18/705,843

Electronic Unit and Mobile Electronic Device for a Drug Delivery Device

Non-Final OA §102§103
Filed
Apr 29, 2024
Priority
Nov 03, 2021 — EU 21315213.5 +1 more
Examiner
PONTON, JAMES D
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sanofi S.A.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
465 granted / 580 resolved
+10.2% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
34 currently pending
Career history
620
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
40.8%
+0.8% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
37.0%
-3.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 580 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 24 is objected to because of the following informalities: Claim 24 is missing “the” before “mobile electronic device” in the final line of the claim. Appropriate correction is required. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “a drive mechanism operatively connectable to the medicament container to expel or to withdraw the medicament from the medicament container” in claim 27. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 18, 20, 21, 24, 25, 27, 29, 31 34 and 35 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hammen et al. (US 2021/0069421 A1, hereafter “Hammen”). As to claim 18, Hammen discloses an electronic circuit for a drug delivery device (602), the drug delivery device being operable to dispense a medicament (abstract, para 0022, 0056), the electronic circuit comprising: a communication interface configured to wirelessly communicate with a mobile electronic device (610; see Fig. 6) and to transmit at least a wireless signal to the mobile electronic device (para 0056-0057), the wireless signal indicating at least one of a distance or a relative position between the electronic circuit and the mobile electronic device (para 0056-0057); and a processor (120) operatively connected to the communication interface and configured to enable, to disable, to trigger, or to terminate execution of an electronically implemented function of the electronic circuit based on an analysis of the at least one of the distance or the relative position (para 0056-0057). As to claim 20, Hammen discloses the electronic circuit according to claim 19, wherein processor is configured to disapprove access to the electronically implemented function of the electronic circuit if the distance is above a predefined approval distance (para 0056-0057). As to claim 21, Hammen discloses the electronic circuit according to claim 18, wherein the processor is further configured to analyze at least one of the distance or the relative position (see para 0056-0057; microcontroller remaining in a sleep state and then entering into an enabled state is effectively an analysis/evaluation of the injection device 602 being within a certain distance of 610). As to claim 24, Hammen discloses the electronic circuit according to claim 18, wherein the processor is operable to enable or to trigger the electronically implemented function only when: the distance between the electronic circuit and the mobile electronic device is within a predefined operating distance, and/or the electronic circuit is within a predefined relative operating position with regard to mobile electronic device (see para 0056-0057 of Hammen). As to claim 25, Hammen discloses the electronic circuit according to claim 18, wherein the processor is configured to generate a control command based on the analysis of at least one of the distance or the relative position, the control command being configured to cause at least one of: locking or unlocking of a drive mechanism of the drug delivery device by an electromechanical interlock (para 0056-0057), or switching the electronic circuit from a standby mode into an active mode (see para 0027 of Hammen mentioning a sleep state (interpreted as a standby mode) and para 0056-0057 mentioning entering an enabled state). As to claim 27, Hammen discloses a drug delivery device (602) operable to dispense a medicament (abstract, para 0022, 0056), the drug delivery device comprising: a housing (103; the examiner points out that 105 and 118 can also be interpreted as parts of the housing) to accommodate a medicament container (104) filled with the medicament (para 0021); a drive mechanism (106) operatively connectable to the medicament container to expel or to withdraw the medicament from the medicament container (para 0022); and an electronic circuit (120, 104, and associated electronic components) integrated into the housing and/or operatively connected to the drive mechanism (see abstract, para 0026, 0027, 0056, 0057), wherein the electronic circuit comprises: a communication interface configured to wirelessly communicate with a mobile electronic device (610; see Fig. 6) and to transmit at least a wireless signal to the mobile electronic device (para 0056-0057), the wireless signal indicating at least one of a distance or a relative position between the electronic circuit and the mobile electronic device (para 0056-0057); and a processor (120) operatively connected to the communication interface and configured to enable, to disable, to trigger, or to terminate execution of an electronically implemented function of the electronic circuit based on an analysis of the at least one of the distance or the relative position (para 0056-0057). As to claim 29, Hammen discloses a method of controlling an electronically implemented function of or associated with a drug delivery device (602), the method comprising: establishing of a wireless communication link between an electronic circuit (120, 104, and associated electronic components) attached to or integrated into the drug delivery device and a mobile electronic device (para 0056-0057); determining at least one of a distance or a relative position between the electronic circuit and the mobile electronic device through transmission of wireless signals between the electronic circuit and the mobile electronic device (para 0056-0057); analyzing or evaluating at least one of the distance or the relative position (see para 0056-0057; microcontroller remaining in a sleep state and then entering into an enabled state is effectively an analysis/evaluation of the injection device 602 being within a certain distance of 610); and at least one of enabling, disabling, triggering or terminating execution of an electronically implemented function of at least one of the electronic circuit or the mobile electronic device based on analyzing or evaluating of the at least one of the distance or the relative position (para 0056-0057). As to claim 31, Hammen discloses the method according to claim 29, further comprising: disapproving access to the electronically implemented function of the electronic circuit if the distance between the electronic circuit and the mobile electronic device is above a predefined approval distance (para 0056-0057). As to claim 34, Hammen discloses the method according to claim 29, further comprising: enabling or triggering the electronically implemented function only when: the distance between the electronic circuit and the mobile electronic device is within a predefined operating distance (para 0056-0057), and/or the electronic circuit is within a predefined relative operating position with regard to mobile electronic device (para 0056-0057). As to claim 35, Hammen discloses the method according to claim 29, further comprising: generating a control command based on the analysis of at least one of the distance or the relative position, the control command being configured to cause at least one of: locking or unlocking of a drive mechanism of the drug delivery device by an electromechanical interlock (para 0056-0057), or switching the electronic circuit from a standby mode into an active mode (see para 0027 of Hammen mentioning a sleep state (interpreted as a standby mode) and para 0056-0057 mentioning entering an enabled state). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 19 is/are rejected under 35 U.S.C. 103 as being unpatentable over Hammen in view of Edwards et al. (US 2019/0279756 A1, hereafter “Edwards”). As to claim 19, Hammen discloses the electronic circuit according to claim 18, but does not expressly recite wherein the electronic circuit is configured to communicate with the mobile electronic device to quantitatively measure the distance between the electronic circuit and the mobile electronic device. Edwards however discloses “A relative position between the mobile computing device and the medicament delivery device can then be determined based on the wireless signal (e.g., if the wireless signal is not received within a time period, or the like). A second notification can then be produced when the relative position exceeds a relative position threshold” (para 0318). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the electronic circuit of Hammen such that the electronic circuit is configured to communicate with the mobile electronic device to quantitatively measure the distance between the electronic circuit and the mobile electronic device. One would have been motivated to do so in order to provide an indication to a user that a distance between mobile electronic device and the electronic circuit has reached a threshold (see para 0318). Claim(s) 18-22, 24, 25, 29-32, 34 and 35 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dharwad (US 2019/0228863) in view of Hammen. As to claim 18, Dharwad discloses an electronic circuit (see electronic components illustrated in Fig. 1 including processor 111, communication interface 112, memory 113, etc..) for a drug delivery device (110; see Fig. 1), the drug delivery device being operable to dispense a medicament (para 0035), the electronic circuit comprising: a communication interface (112) configured to wirelessly communicate with a computer and to transmit at least a wireless signal to the computer, the wireless signal indicating at least one of a distance or a relative position between the electronic circuit and the computer (para 0019-0022, 0040-0043, Fig 3); and a processor operatively connected to the communication interface and configured to enable, to disable, to trigger, or to terminate execution of an electronically implemented function of the electronic circuit based on an analysis of the at least one of the distance or the relative position (para 0019-0022, 0040-0043, Fig 3). Dharwad does not expressly recite that the computer is a mobile electronic device. Hammen teaches a drug delivery device (602; Fig. 6) that wirelessly communicates with a mobile electronic device (610) (see para 0056, 0057). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Dharwad such that the computer (if not already) is a mobile electronic device. One would have been motivated to do so as one possible implementation of the computer, and to allow/change operation of the drug delivery based on proximity to the mobile electronic device (see para 0056, 0057 of Hammen). As to claim 19, Dharwad in view of Hammen teaches the electronic circuit according to claim 18 as described above, and further wherein the electronic circuit is configured to communicate with the mobile electronic device to quantitatively measure the distance between the electronic circuit and the mobile electronic device (see modification above and para 0019-0022, 0040-0043, Fig 3 of Dharwad). As to claim 20, Dharwad in view of Hammen teaches the electronic circuit according to claim 19, wherein processor is configured to disapprove access to the electronically implemented function of the electronic circuit if the distance is above a predefined approval distance (para 0019-0022, 0040-0043, Fig 3 of Dharwad). As to claim 21, Dharwad in view of Hammen teaches the electronic circuit according to claim 18 as described above, and further wherein the processor is further configured to analyze at least one of the distance or the relative position (see para 0019-0022, 0040-0043, Fig 3 of Dharwad). As to claim 22, Dharwad in view of Hammen teaches the electronic circuit according to claim 18 as described above, and further a proximity sensor operatively connected to the processor and configured to measure at least one of the distance or the relative position between the electronic circuit and the mobile electronic device (see para 0019-0022, 0040-0043, Fig 3 of Dharwad, also see para 0056-0057 of Hammen). As to claim 24, Dharwad in view of Hammen teaches the electronic circuit according to claim 18 as described above, and further wherein the processor is operable to enable or to trigger the electronically implemented function only when: the distance between the electronic circuit and the mobile electronic device is within a predefined operating distance, and/or the electronic circuit is within a predefined relative operating position with regard to mobile electronic device (see para 0019-0022, 0040-0043, Fig 3 of Dharwad, also see para 0056-0057 of Hammen). As to claim 25, Dharwad in view of Hammen teaches the electronic circuit according to claim 18 as described above, and further wherein the processor is configured to generate a control command based on the analysis of at least one of the distance or the relative position, the control command being configured to cause at least one of: generating a user-perceivable alert or signal by a signaling unit (see para 0038, 0042, 0066 of Dharwad teaching alerts), locking or unlocking of a drive mechanism of the drug delivery device by an electromechanical interlock (see para 0066, 0071 of Dharwad mentioning locking infusion capabilities), triggering or terminating transmission of data by the communication interface (see para 0071 of Dharwad), or switching the electronic circuit from a standby mode into an active mode (see para 0027 of Hammen mentioning a sleep state (interpreted as a standby mode) and para 0056-0057 mentioning entering an enabled state). As to claim 29, Dharwad discloses a method of controlling an electronically implemented function of or associated with a drug delivery device (110; see Fig. 1), the method comprising: establishing of a wireless communication link between an electronic circuit (see electronic components illustrated in Fig. 1 including processor 111, communication interface 112, memory 113, etc..) attached to or integrated into the drug delivery device (110) and a computer (120); determining at least one of a distance or a relative position between the electronic circuit and the computer through transmission of wireless signals between the electronic circuit and computer (para 0019-0022); analyzing or evaluating at least one of the distance or the relative position (para 0019-0022, 0040); and at least one of enabling, disabling, triggering or terminating execution of an electronically implemented function of at least one of the electronic circuit or the mobile electronic device based on analyzing or evaluating of the at least one of the distance or the relative position (para 0019-0022, 0040-0043, Fig 3). Dharwad does not expressly recite that the computer is a mobile electronic device. Hammen teaches a drug delivery device (602; Fig. 6) that wirelessly communicates with a mobile electronic device (610) (see para 0056, 0057). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Dharwad such that the computer (if not already) is a mobile electronic device. One would have been motivated to do so as one possible implementation of the computer, and to allow/change operation of the drug delivery based on proximity to the mobile electronic device (see para 0056, 0057 of Hammen). As to claim 30, Dharwad in view of Hammen teaches the method according to claim 29, further comprising: quantitatively measuring the distance between the electronic circuit and the mobile electronic device (see modification above and para 0019-0022, 0040-0043, Fig 3 of Dharwad). As to claim 31, Dharwad in view of Hammen teaches the method according to claim 29, further comprising: disapproving access to the electronically implemented function of the electronic circuit if the distance between the electronic circuit and the mobile electronic device is above a predefined approval distance (para 0019-0022, 0040-0043, Fig 3 of Dharwad). As to claim 32, Dharwad in view of Hammen teaches the method according to claim 29, further comprising: measuring at least one of the distance or the relative position between the electronic circuit and the mobile electronic device by using a proximity sensor operatively connected to the processor (see para 0019-0022, 0040-0043, Fig 3 of Dharwad, also see para 0056-0057 of Hammen). As to claim 34, Dharwad in view of Hammen teaches the method according to claim 29, further comprising: enabling or triggering the electronically implemented function only when: the distance between the electronic circuit and the mobile electronic device is within a predefined operating distance (para 0019-0022, 0040-0043, Fig 3 of Dharwad), and/or the electronic circuit is within a predefined relative operating position with regard to mobile electronic device (para 0019-0022, 0040-0043, Fig 3 of Dharwad). As to claim 35, Dharwad in view of Hammen teaches the method according to claim 29, further comprising: generating a control command based on the analysis of at least one of the distance or the relative position, the control command being configured to cause at least one of: generating a user-perceivable alert or signal by a signaling unit (see para 0038, 0042, 0066 of Dharwad teaching alerts), locking or unlocking of a drive mechanism of the drug delivery device by an electromechanical interlock (see para 0066, 0071 of Dharwad mentioning locking infusion capabilities), triggering or terminating transmission of data by the communication interface (see para 0071 of Dharwad), or switching the electronic circuit from a standby mode into an active mode (see para 0027 of Hammen mentioning a sleep state (interpreted as a standby mode) and para 0056-0057 mentioning entering an enabled state). Claim(s) 23 and 33 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dharwad in view of Hammen as applied to claim 22 above, and further in view of Galasso et al. (US 2011/0184264 A1, hereafter “Galasso”). As to claim 23, Dharwad in view of Hammen teaches the electronic circuit according to claim 22 as described above, but does not expressly recite wherein at least one of the communication interface or the proximity sensor is implemented as an ultra-wideband (UWB)- based interface or an UWB-based sensor, respectively, and is configured to generate, to transmit, to receive and/or to process electromagnetic ultra-wideband signals. Galasso teaches “The communication unit can be configured for wired or wireless communication, including, but not limited to, radio frequency (RF) communication (e.g., Radio-Frequency Identification (RFID), Zigbee communication protocols, WiFi, infrared, wireless Universal Serial Bus (USB), Ultra Wide Band (UWB), Bluetooth.RTM. communication protocols, and cellular communication, such as code division multiple access (CDMA) or Global System for Mobile communications (GSM). In one embodiment, analyte meter 100 includes a wireless communication unit, wherein the wireless communication unit is configured for bi-directional radio frequency (RF) communication with other devices to transmit and/or receive data to and from the analyte meter 100” (para 0200; also see para 0007-0018). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Dharwad (as already modified above) such that wherein at least one of the communication interface or the proximity sensor is implemented as an ultra-wideband (UWB)- based interface or an UWB-based sensor, respectively, and is configured to generate, to transmit, to receive and/or to process electromagnetic ultra-wideband signals. One would have been motivated to do so as an additional or alternative means of communication (see para 0007-0018, 0200 of Galasso). As to claim 33, Dharwad in view of Hammen teaches the method according to claim 32 as described above, but does not expressly recite wherein measuring at least one of the distance or the relative position between the electronic circuit and the mobile electronic device comprises generating, transmitting, receiving and/or processing electromagnetic ultra-wideband signals. Galasso teaches “The communication unit can be configured for wired or wireless communication, including, but not limited to, radio frequency (RF) communication (e.g., Radio-Frequency Identification (RFID), Zigbee communication protocols, WiFi, infrared, wireless Universal Serial Bus (USB), Ultra Wide Band (UWB), Bluetooth.RTM. communication protocols, and cellular communication, such as code division multiple access (CDMA) or Global System for Mobile communications (GSM). In one embodiment, analyte meter 100 includes a wireless communication unit, wherein the wireless communication unit is configured for bi-directional radio frequency (RF) communication with other devices to transmit and/or receive data to and from the analyte meter 100” (para 0200; also see para 0007-0018). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Dharwad (as already modified above) such that measuring at least one of the distance or the relative position between the electronic circuit and the mobile electronic device comprises generating, transmitting, receiving and/or processing electromagnetic ultra-wideband signals. One would have been motivated to do so as an additional or alternative means of communication (see para 0007-0018, 0200 of Galasso). Claim(s) 26 and 36 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dharwad in view of Hammen as applied to claim 18 above, and further in view of Chalberg, Jr. et al. (US 2020/0206025 A1, hereafter “Chalberg”). As to claim 26, Dharwad in view of Hammen teaches the electronic circuit according to claim 18 as described above, but does not expressly recite wherein the communication interface is configured to exchange user specific data of a user with the mobile electronic device, wherein the user specific data specify at least one of:a medicament type, a time and/or a date of a medicament dispensing action, an amount of dispensed medicament, or motion of the user. Chalberg discloses “the devices are “smart”, such that they include one or more electronic components that are configured to provide for wireless communication at least between an active agent delivery component and an actuator component of the device, if not with one or more additional networked devices” (para 0038; also see para 0087, 0094, 0118 regarding wireless communication), and “the active agent delivery component determination comprises usage information. Usage information is data about actual use of the active agent delivery component in the delivery of an active agent composition thereof to a subject. Such usage information includes, but is not limited to: information that an active agent composition was delivered from an active agent delivery component (e.g., during an administration event), where such information may include temporal information, such as date and time information, etc.; location or geographical information, such as where the usage took place; information about the disease condition for which the active agent delivery component was employed; information about the subject with which the active agent delivery component was employed, where such information may include one or more of: age, sex, disease condition, unique identity, co-morbid conditions and concomitant medications, medical history, and the like” (para 0129). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Dharwad (as already modified above) such that the communication interface is configured to exchange user specific data of a user with the mobile electronic device, wherein the user specific data specify at least one of: a medicament type, a time and/or a date of a medicament dispensing action, or an amount of dispensed medicament. One would have been motivated to do so to provide a means of communicating such information to the mobile electronic device (see para 0038, 0087, 0094, 0118, 0129 of Chalberg). As to claim 36, Dharwad in view of Hammen teaches the method according to claim 29 as described above, but does not expressly recite: exchanging user specific data of a user between the communication interface and the mobile electronic device, wherein the user specific data specify at least one of: a medicament type, a time and/or a date of a medicament dispensing action, an amount of dispensed medicament, or motion of the user. Chalberg discloses “the devices are “smart”, such that they include one or more electronic components that are configured to provide for wireless communication at least between an active agent delivery component and an actuator component of the device, if not with one or more additional networked devices” (para 0038; also see para 0087, 0094, 0118 regarding wireless communication), and “the active agent delivery component determination comprises usage information. Usage information is data about actual use of the active agent delivery component in the delivery of an active agent composition thereof to a subject. Such usage information includes, but is not limited to: information that an active agent composition was delivered from an active agent delivery component (e.g., during an administration event), where such information may include temporal information, such as date and time information, etc.; location or geographical information, such as where the usage took place; information about the disease condition for which the active agent delivery component was employed; information about the subject with which the active agent delivery component was employed, where such information may include one or more of: age, sex, disease condition, unique identity, co-morbid conditions and concomitant medications, medical history, and the like” (para 0129). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Dharwad (as already modified above) to include exchanging user specific data of a user between the communication interface and the mobile electronic device, wherein the user specific data specify at least one of: a medicament type, a time and/or a date of a medicament dispensing action, or an amount of dispensed medicament. One would have been motivated to do so to provide a means of communicating such information to the mobile electronic device (see para 0038, 0087, 0094, 0118, 0129 of Chalberg). Claim(s) 28 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shabbach (US 2013/0197445 A1) in view of Hammen. As to claim 28, Shabbach discloses a supplementary device (2; see Figs. 2a, 4) for a drug delivery device (1), the supplementary device comprising: a housing (20); a fastener (mating unit 20-1, 20-2) for fastening the supplementary device to a housing (10) of the drug delivery device (1) (see abstract, para 0112, 0262); and an electronic circuit (electronic components seen in Fig. 4), wherein the electronic circuit comprises: a communication interface (28) configured to wirelessly communicate with a mobile electronic device and to transmit at least a wireless signal to the mobile electronic device (para 0120, 0137); and a processor (24) operatively connected to the communication interface (Fig. 4, para 0137).. Shabbach does not expressly recite the wireless signal indicating at least one of a distance or a relative position between the electronic circuit and the mobile electronic device and the processor configured to enable, to disable, to trigger, or to terminate execution of an electronically implemented function of the electronic circuit based on an analysis of the at least one of the distance or the relative position. Hammen discloses an electronic circuit (120, 104, and associated electronic components) integrated into the housing and/or operatively connected to the drive mechanism (see abstract, para 0026, 0027, 0056, 0057), wherein the electronic circuit comprises: a communication interface configured to wirelessly communicate with a mobile electronic device (610; see Fig. 6) and to transmit at least a wireless signal to the mobile electronic device (para 0056-0057), the wireless signal indicating at least one of a distance or a relative position between the electronic circuit and the mobile electronic device (para 0056-0057); and a processor (120) operatively connected to the communication interface and configured to enable, to disable, to trigger, or to terminate execution of an electronically implemented function of the electronic circuit based on an analysis of the at least one of the distance or the relative position (para 0056-0057). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Shabbach in view of Hammen such that the wireless signal indicates at least one of a distance or a relative position between the electronic circuit and the mobile electronic device and the processor configured to enable, to disable, to trigger, or to terminate execution of an electronically implemented function of the electronic circuit based on an analysis of the at least one of the distance or the relative position. One would have been motivated to do so in order to control operation of the drug delivery device based on proximity to the mobile electronic device (see para 0056-0057 of Hammen). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to James D Ponton whose telephone number is (571)272-1001. The examiner can normally be reached M-F 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /James D Ponton/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Apr 29, 2024
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788943
DRUG SOLUTION INJECTION NEEDLE AND DRUG SOLUTION INJECTION NEEDLE SYSTEM
4y 2m to grant Granted Nov 10, 2026
Patent 12788873
PRECISION PUMP WITH AUTOMATIC VALVE SWITCHING AND LOW TOLERANCE STACK-UP USING SIDE PORTED CANNULA FOR SMALL VOLUME PUMPING
4y 1m to grant Granted Nov 10, 2026
Patent 12788892
ASPIRATION DEVICE INCLUDING AIR PURGE TIP
3y 11m to grant Granted Nov 10, 2026
Patent 12779111
SKIN PATCH DRUG INFUSION DEVICE
3y 4m to grant Granted Nov 03, 2026
Patent 12779131
MODULAR INJECTION SYSTEM
3y 4m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+31.6%)
2y 10m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 580 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month